CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
Advanced insights from CytoReason’s disease models will support Pfizer’s drug development processTEL AVIV, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) --...
pcc Practice Builder™ Emerges as a Growth Engine for Medical Practices in 2026